To learn more about our clinical trial programs please visit www.clinicaltrials.gov or click on one of the following links:
- STOP-HE: Phase 2b study of OCR-002 in patients with hepatic encephalopathy (HE)
American Association for the Study of Liver Diseases
American Gastroenterological Association (AGA)
National Digestive Diseases Information Clearinghouse (NDDIC)
United Network for Organ Sharing
EASL 2017 “The International Liver Congress”
- Early increase in ammonia is a feature of non-alcoholic fatty liver disease and the ammonia lowering drug, ornithine phenylacetate (OCR-002) prevents progression of fibrosis in a rodent model
EASL 2016 “The International Liver Congress”
- Beneficial effects of ornithine phenylacetate to attenuate muscle mass loss and to prevent hepatic encephalopathy in experimental cirrhosis – Bosoi EASL 2016 poster
- Hemichannel-Mediated Release of Lactate in Health and Disease – Hadjihambi EASL 2016 abstract
AASLD 2016 “The Liver Meeting”
AASLD 2015 “The Liver Meeting”
Important Information regarding Links
Upon selecting one of the above links, you will leave the Ocera website. Ocera assumes no responsibility for information or statements you encounter on the internet outside of the Ocera website.
The information contained on this page is intended for US patients and healthcare professionals only.